Alpha 1-protease inhibitor in serous effusions: differences in lectin crossed immuno-affinoelectrophoresis precipitin profiles between benign and malignant disease.
Differences in the lectin crossed immuno-affinoelectrophoresis (LCIE) precipitin profile of the antiprotease alpha 1-protease inhibitor (alpha 1-PI) have been detected between serous effusions of benign and malignant origin. Extra proteins with antigenicity towards anti-human alpha 1-PI appear in both malignant pleural effusions and malignant ascitic fluid caused by ovarian cancer that are not detected in effusions of benign origin. These compounds may be protease-antiprotease complexes caused by tumour excretion of proteases into the serous effusions.
D001202:Ascitic Fluid / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis*; D002241:Carbohydrates; D004194:Disease / Q000378:metabolism*; D005260:Female; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional / Q000379:methods; D037102:Lectins; D010051:Ovarian Neoplasms / Q000378:metabolism*; D010996:Pleural Effusion / Q000378:metabolism*; D011480:Protease Inhibitors / Q000032:analysis*; D014357:Trypsin / Q000378:metabolism; D000515:alpha 1-Antitrypsin
D001798:Blood Proteins; D002241:Carbohydrates; D037102:Lectins; D011480:Protease Inhibitors; D000515:alpha 1-Antitrypsin; D014357:Trypsin